402 results on '"Selleslag, D."'
Search Results
2. Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL
3. P135 - Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
4. Postremission cytopenia management in patients with AML treated with venetoclax and azacitidine in VIALE-A
5. Parvovirus B19-triggered hemophagocytic lymphohistiocytosis in a patient with Crohn’s disease
6. Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes
7. P699: REAL-LIFE OUTCOMES OF PONATINIB TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) OR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL): 5-YEAR-DATA FROM A BELGIAN REGISTRY
8. P498: CLINICAL AND BIOLOGICAL MARKERS ASSOCIATED WITH LONG-TERM SURVIVAL FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN REMISSION AFTER CHEMOTHERAPY IN THE QUAZAR AML-001 TRIAL OF ORAL AZACITIDINE
9. P366: BLINATUMOMAB ADDED TO PREPHASE AND CONSOLIDATION THERAPY IN NEWLY DIAGNOSED PRECURSOR B-ALL IN ADULTS. A PHASE II HOVON TRIAL
10. P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY.
11. Intensive Chemotherapy Followed by Stem Cell Transplantation for the Treatment of Myelodysplastic Syndromes
12. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation
13. European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization
14. An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole
15. IMMUNOGENICITY AND SAFETY OF 4 DOSES OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FOLLOWED BY 1 DOSE OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS AGED ≥2 YEARS: AN OPEN LABEL CLINICAL TRIAL: PH-O151
16. Primary immune thrombocytopenia in adults: Belgian recommendations for diagnosis and treatment anno 2021 made by the Belgian Hematology Society.
17. Primary immune thrombocytopenia in adults: Belgian recommendations for diagnosis and treatment anno 2021 made by the Belgian Hematology Society.
18. Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups
19. A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias
20. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias
21. PHASE 2 STUDY OF PEVONEDISTAT + AZACITIDINE VERSUS AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES/CHRONIC MYELOMONOCYTIC LEUKEMIA OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA (NCT02610777)
22. The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921)
23. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study
24. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors
25. Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing
26. A novel recurrent translocation t(11;14)(p11;q32) in splenic marginal zone B cell lymphoma
27. Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF
28. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells
29. Defining opportunistic invasive Fungal infections in immunocompromised patients with Cancer and Hematopoietic stem cell transplants: An international consensus
30. Haematopoietic stem cell mobilization with plerixafor in patients with non-haematological diseases: P1202
31. Autologous haematopoietic stem cell mobilization with plerixafor and G-CSF: impact of apheresis volume. Data from the Plerixafor European Compassionate Use Study: P1083
32. The role of the CXCR4 antagonist Plerixafor® in elderly patients failing autologous stem cell mobilization. Data from the Plerixafor Compassionate Use Study. On behalf of the European Consortium for Stem Cell Mobilization (ECOSM): P1073
33. Autologous haematopoietic stem cell mobilization with plerixafor and G-CSF: impact of overweight and obesity: P1077
34. Plerixafor for stem cell mobilization in Hodgkin, non- Hodgkin, and multiple myeloma patients: a subgroup analysis from the European Compassionate Use Program: P1075
35. Patient and disease characteristics influencing the outcome of mobilization with plerixafor: large compassionate-use analysis by ECOSM (European Consortium for Stem Cell Mobilization): O377
36. Acute thyrotoxicosis after SCT
37. Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: A phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group
38. Dual infection with polyomavirus BK and acyclovir-resistant herpes simplex virus successfully treated with cidofovir in a bone marrow transplant recipient
39. Retrospective comparison of reduced-intensity conditioning and conventional myeloablative conditioning for allogeneic haematopoietic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes
40. New prognostic score based on clinical and biologic factors in patients < 56 years with poor-risk MDS and AML treated with intensive treatment
41. Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: A clinical and erythrokinetic assessment
42. Role of ATG in fludarabine phosphate-based nonmyeloablative stem cell transplantation: a national dose-finding study
43. The impact of post-remission therapy on outcome of patients with poor risk MDS and secondary AML (sAML) treated with intensive chemotherapy with or without stem cell transplantation in a joint study
44. Evaluation of serum galactomannan ELISA during caspofungin therapy: results from the Caspofungin Salvage Invasive Aspergillosis Study
45. Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group
46. Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT
47. PS937 RANDOMIZED PHASE III HOVON-100 STUDY OF CLOFARABINE COMBINED WITH STANDARD TREATMENT IN ADULT PATIENTS WITH NEWLY DIAGNOSED ALL
48. PF696 SAFETY AND EFFICACY OF SELF-ADMINISTERED ROMIPLOSTIM IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP): RESULTS OF AN INTEGRATED ANALYSIS OF FIVE CLINICAL TRIALS
49. PF694 TREATMENT-FREE REMISSION AFTER TPO RECEPTOR AGONISTS IN ADULT ITP PATIENTS IN BELGIUM
50. A single dose of donor lymphocytes depleted of anti-host reactive T cells (ATIR101) following T-cell-depleted haploidentical HSCT is safe and efficaceous
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.